Advance
the evidence.
Coordinate rigorous trials, meaningful outcomes, and transparent adverse event reporting.
Research American Academy of Novel Therapeutics
A new frontier.
A higher standard.
An independent voice.
A shared responsibility.
- Founding year
- 2026
- Governing boards
- 03
- Therapeutic areas
- 07
- Open board seats
- 20
01 / The AcademyPromise, guided by principle
New therapeutics are changing the questions medicine can ask. We exist to raise the standard of the answers.
The American Academy of Novel Therapeutics is a medical society for clinicians, scientists, and regulators working on psychedelic and emerging treatments.
Our founding mission: connect rigorous research, responsible policy, and competent clinical practice so that therapeutic promise can be evaluated with patient safety at its center.
Advance
Inform
the framework.
Bring an independent clinical perspective to regulators, legislators, and medical boards.
RegulationDefine
responsible care.
Develop screening, monitoring, and training standards grounded in evidence and ethics.
PracticeWiden
the possibility.
Work toward lawful, equitable access for veterans and people living with difficult-to-treat illness.
Access02 / Therapeutic landscapeSeven areas. One standard of rigor.
From psychedelic compounds to next-generation psychoplastogens, we follow the evidence, and the questions that remain.
| Compound / class | Research focus | Development context | Academy priority |
|---|---|---|---|
| 01PsilocybinPsilocybe spp. | Depression, end-of-life distress, alcohol use disorder | Clinical researchState pathways are distinct from FDA approval. | Evidence-based care and practitioner training |
| 02IbogaineTabernanthe iboga | Substance use disorders; exploratory PTSD and TBI research | Safety-critical researchCardiac risk requires particular scrutiny. | Cardiac safety and monitored research protocols |
| 03MDMAEntactogen | Post-traumatic stress disorder | Clinical researchStudy quality and independent assessment matter. | Independent outcomes assessment and trial integrity |
| 04Ketamine / esketamineDissociative therapeutics | Treatment-resistant depression and depressive symptoms | Approved / off-label*Different products have different indications. | Outpatient standards, monitoring, and continuity of care |
| 05LSDClassic psychedelic | Anxiety disorders | Clinical researchEvidence is specific to product and indication. | Trial design and long-term outcome evaluation |
| 065-MeO-DMTShort-acting psychedelic | Depression | Clinical researchSafety and durable benefit remain key questions. | Safety assessment and responsible clinical translation |
| 07PsychoplastogensNon-hallucinogenic candidates | Depression, substance use disorders | Early developmentA class of candidates, not a single medicine. | Scalable approaches to neuroplasticity-based care |
Research interests do not establish safety, efficacy, or approval. This overview is not a live trial-phase tracker.
*Esketamine has FDA-approved depression indications and a REMS program; psychiatric use of ketamine is off-label. Prevention of suicide has not been established for esketamine. FDA prescribing information ↗ · NIDA research overview ↗
03 / Founding leadership20 open seats
Three boards. Complementary expertise. A shared commitment to independent judgment.
Nominate yourself or a colleagueBring clarity to
complex pathways.
Advises on FDA, DEA, and state pathways: scheduling, IND strategy, breakthrough designation, REMS, and state access programs.
01Open seat
Board Chair
Former FDA or DEA senior official, or regulatory counsel with controlled-substance experience.
02Open seat
Drug Development
CNS drug development experience from investigational application through marketing review.
03Open seat
State Policy
Experience building or administering state psychedelic programs or research appropriations.
04Open seat
Health Law
Medical board, scope-of-practice, controlled-substance, and liability expertise.
05Open seat
Veterans Affairs
A connection to VA research and veteran service organizations advancing responsible access.
06Open seat
Patient Representative
Lived experience with these therapies and a clear perspective on barriers to care.
Put patient safety
at the center.
Develops clinical standards, reviews adverse events, and guides the planned credentialing program through multidisciplinary clinical expertise.
01Open seat
Chair, Psychiatry
Board-certified psychiatrist with published psychedelic trial experience.
02Open seat
Cardiology
Electrophysiology or cardiology expertise in QT prolongation and arrhythmia screening.
03Open seat
Addiction Medicine
Board-certified addiction specialist with opioid withdrawal management experience.
04Open seat
Anesthesiology
Sedation, airway, and monitored-care expertise across clinical settings.
05Open seat
Emergency Medicine
Rescue protocols and transfer criteria for care outside the hospital.
06Open seat
Clinical Psychology
Preparation, integration, and evidence-based facilitator training.
07Open seat
Pharmacology
Medication interactions, contraindications, and compound-specific safety.
08Open seat
Nursing
Bedside monitoring standards, staffing, and continuity of care.
Ask better questions.
Build stronger evidence.
Directs the research agenda, reviews proposed grants, and develops the outcomes registry with academic and independent investigators.
01Open seat
Research Chair
Principal investigator on a completed Phase 2 or 3 psychedelic trial.
02Open seat
Neuroscience
Mechanism, neuroplasticity research, and psychoplastogen development.
03Open seat
Biostatistics
Trial design, blinding integrity, and registry methodology.
04Open seat
Ibogaine Research
Human ibogaine research experience in safety or clinical outcomes.
05Open seat
Computational Medicine
Predictive models for screening, dose response, and outcome tracking.
06Open seat
Ethics & Indigenous Relations
Benefit-sharing, reciprocity, and consent for plant-derived medicines.
Independent judgment is essential. Nominees should include a short bio and disclose financial relationships with drug developers or clinics.
04 / Safety & ethicsThe foundation of responsible progress
Our founding framework puts patient safety, informed consent, and transparent evidence at the heart of every conversation.
Proposed framework · Medical Board review- 01
Cardiac safety
Compound-specific cardiac assessment, monitoring, and emergency planning, with particular attention to ibogaine.
- 02
Psychiatric screening
Structured assessment of psychiatric history, vulnerability, and suitability before treatment.
- 03
Medication review
Documented interaction assessment and individualized medication decisions by the treating clinician.
- 04
Qualified clinical teams
Appropriate licensed oversight, trained monitors, and clear escalation and transfer pathways.
- 05
Continuity & integration
A structured follow-up plan, ongoing support, and attention to longer-term outcomes.
- 06
Transparent safety reporting
Prompt adverse event reporting under applicable requirements, with privacy-protecting analysis.
- 07
Meaningful informed consent
Clear discussion of evidence quality, legal status, alternatives, uncertainty, and known risks.
- 08
Independent judgment
Disclosure and management of financial interests in recommended products and facilities.
05 / Research agendaA founding roadmap, 2026 to 2028
Our proposed first three years focus on safety, credible evidence, and the foundations for responsible access.
2026Build the foundation
01
Outcomes registry
Develop a national, de-identified registry of treatments, adverse events, and long-term outcomes.
02
Ibogaine cardiac safety
Convene experts to develop and review a cardiac screening and monitoring consensus framework.
2027Translate into practice
03
Practitioner credential
Develop a defensible training and examination standard for responsible clinical practice.
04
AI-assisted screening
Study whether predictive models can help identify elevated risk using clinical and medication data.
2028Create responsible pathways
05
Veteran access
Pursue collaboration with VA and state consortia on lawful domestic research and access pathways.
06
Psychoplastogen research
Support early studies of non-hallucinogenic candidates for scalable outpatient care.
Planned initiatives are subject to board approval, funding, and applicable regulatory requirements.
06 / MembershipBe part of the founding chapter
Bring your experience, your questions, and your commitment to better care. Help shape the Academy from the beginning.
Clinical leadershipFounding membership
Fellow
FAAONT · Upon fellowship approval
Licensed physicians, psychologists, nurse practitioners, and PharmDs with relevant clinical or research experience.
$495/ year
Apply as a Fellow- Board and committee eligibility
- Planned credentialing program access
- Voting rights
- Public member directory listing
Research & discovery
Associate
Researchers & trainees
Scientists, residents, graduate students, and allied health professionals advancing research and clinical programs.
$195/ year
Apply as an Associate- Research Council working groups
- Registry access for approved studies
- Planned conference and journal access
Policy & partnership
Affiliate
Policy, advocacy & industry
Regulators, legislative staff, attorneys, veteran organizations, patient advocates, and industry professionals.
$95/ year
Apply as an Affiliate- Policy briefings
- Regulatory Board observer eligibility
- Planned annual meeting access
Dues are waived for founding board members and veterans.
Industry employees may join as Affiliates but may not hold voting seats. Programs and benefits are being established. Membership is not a medical license or specialty board certification.07 / Start a conversationWe welcome thoughtful contributions
Apply for membership, nominate a board member, propose a collaboration, or request a policy briefing.
contact@aaont.orgIndependent science.
Shared standards.
Better possibilities.